about
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells.Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: a retrospective study.Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis.Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry.Heparin monitoring: clinical outcome and practical approach.Perioperative management of patients on direct oral anticoagulants.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsAssociation Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.Dose tailoring of dabigatran etexilate: obvious or excessive?Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.Laboratory Assessment of Direct Oral Anticoagulants.Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.Inactivation of human coagulation factor X by a protease of the pathogen Capnocytophaga canimorsus.Target-Specific Oral Anticoagulants-New Approaches in the Field of Oral Anticoagulation.Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory TestsClinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS).Measuring Direct Oral Anticoagulants.Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians.Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.Application of a clot-based assay to measure the procoagulant activity of stored allogeneic red blood cell concentrates.An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants.Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.Impact of the Direct Oral Anticoagulants on Activated Clotting Time.Comparison of five D-dimer reagents and application of an age-adjusted cut-off for the diagnosis of venous thromboembolism in emergency department.Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-Reply.Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.Is Thrombin Time useful for the assessment of dabigatran concentrations? An in vitro and ex vivo study.Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study.The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generationRivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective studyImpact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate
P50
Q30241189-46D95162-DEAD-460D-8CE9-86AD2A8F9A19Q30671427-A908E444-DCAF-477D-B07D-A9F9EBA653AFQ33408683-5BC362FA-47E0-4FCF-ADFB-7D98B47017ACQ33412242-24FEC5F4-AA51-40D5-ADAF-7706CC01996BQ33413076-F63C80FF-6E2E-4310-B2E0-E94BB597FD83Q33436800-2B2A52C3-32D1-4EE2-8568-94199904AA81Q33692054-F8E1301C-F22A-41E5-A4A5-B5EAB8F3EDD1Q33854667-278D91AC-89E1-4A3B-87D8-25AF05052A14Q34207558-F8FAF4D6-BBC5-43DC-85D3-DD92AC7C459AQ35154142-711538AE-3EFC-4186-AC47-14C7B8040AF3Q35674404-E044E0E3-F5A5-43A7-99F9-8836D69CDF26Q35915140-179DEEDC-8EB7-47A0-9B65-94A4DF17D93FQ38046007-92EC46CA-4FCD-4D82-A2C5-B08F7E61F765Q38218292-059C5F55-7ABF-461F-AA02-E47ED7525BE2Q38494667-8151044A-90F4-45B8-9F41-C8BCAA8729FCQ38901666-6A62EC2C-5FDE-4F43-9277-F5CAB255A82BQ38935427-8263EAA0-D41C-430F-B72D-37AF27311A23Q39448172-E51DF2DF-2B00-492C-8361-EBF3BFEE03B4Q40393100-2ADEF018-5D47-4292-9F78-4F2039901ACFQ41589357-62CA536B-8A5A-4962-B90C-60ED746EA175Q42378762-55DA1C92-FC77-4056-A788-5BDBC495AC83Q46209173-738C6A6D-AF8A-4C11-A641-BBEC85B8DD52Q46578398-B73D216C-C915-4FD9-800A-B100533B3B07Q48199813-EB18FDD0-68DC-4E3E-A5B5-B404F5B71FBDQ50077941-E2400E8F-7E03-4EAB-AA7A-B18BA8DEFC56Q50213613-AF6DA607-1A6E-4BD3-AF9A-41225D590F68Q50541388-500ECB22-737F-4F3A-8496-03D03E207F38Q50893821-215E0DB4-61AA-4C85-801E-03D7DDDB74B6Q50909355-CE6F0897-8E3C-4E9A-AA1E-8CCA031429C2Q51046235-F48D3D41-B44E-4918-9B1C-ECB2384CD57EQ51771819-E4D30322-A5F2-47EE-B94F-E69CBEE6ACEBQ53086408-AE756DFC-E52E-4D01-8BCD-69DEA6B615F0Q53154416-772901CB-36E0-4297-A42A-B77CA8B2221BQ53298813-75F4E295-4F38-4745-ADE0-F6B20326ED4EQ53302603-9709B2D3-B0DE-480B-B7A9-31CEC36FE03FQ53392830-0D2EBEED-CE46-4466-BB30-657F42BCB97BQ54560809-F7107354-154B-415B-A0DA-469808699B75Q57482671-4BD65D90-2CB3-4B02-ABCA-824418999E26Q59129911-421B78E3-53C4-4C08-A9AB-AB48310CE1ABQ83719347-15A35A81-69CE-4DC5-A3B3-313A4C45A031
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jonathan Douxfils
@ast
Jonathan Douxfils
@en
Jonathan Douxfils
@es
Jonathan Douxfils
@nl
type
label
Jonathan Douxfils
@ast
Jonathan Douxfils
@en
Jonathan Douxfils
@es
Jonathan Douxfils
@nl
prefLabel
Jonathan Douxfils
@ast
Jonathan Douxfils
@en
Jonathan Douxfils
@es
Jonathan Douxfils
@nl
P108
P106
P1153
55156364000
P21
P31
P496
0000-0002-7644-5298